Literature DB >> 30787448

Expression profile and bioinformatics analysis of COMMD10 in BALB/C mice and human.

Yao Fan1, Longshan Zhang1, Yaling Sun1, Mi Yang1, Xiaoqing Wang1, Xixi Wu1, Weiqiang Huang1, Longhua Chen2, Suming Pan3, Jian Guan4.   

Abstract

COMMD10, a member of COMMD protein, has been proved to target p65 NF-kappaB (nuclear factor-kappaB) subunit and reduce its nuclear translocation, thereby leading to the inactivation of NF-kappaB pathway and suppression of colorectal cancer invasion and metastasis. The aim of this study is to explore its expression pattern and tissue distribution in human normal tissues and other tumor tissues and to investigate the relevant mechanism. We firstly provided the expression profile and histological distribution of COMMD10 in various BALB/c mice tissues and identified the biological distribution of COMMD10 in different kinds of human normal and tumor tissues. We verified the expression profile of COMMD10 using TCGA database. The interacting genes of COMMD10 were predicted by using STRING using. Finally, we performed database, and the microRNAs targeting COMMD10 were predicted using miRDB, miRWalk, TargetScan and microRNA. GO and KEGG pathway analyses were performed to predict the biological function of COMMD10 and its interacting genes. mRNA expression of COMMD10 showed the highest level in the lung and spleen, and the lowest level in the heart and brain. Immunohistochemistry detection revealed that COMMD10 was expressed in different tissues with different degrees and was was located mainly in the cytoplasm. Subsequently, we showed that COMMD10 displayed various degrees of expression in different human normal tissues that mainly located in cytoplasm, while COMMD10 of liver cells resided in both nucleus and cytoplasm. All the tumor tissues except breast small cell carcinoma, breast phyllodes tumor, lung adenocarcinoma, thymoma, cervical cancer and bladder urothelial carcinoma showed that COMMD10 was positive staining in cytoplasm. Kaplan-Meier plotter indicated that renal clear cell carcinoma patients with increased expression level of COMMD10 exhibited longer survival. STRING database revealed that COMMD10 had 41 interacting genes, and data from 4 different databases indicated that hsa-miR-590-3p may be the potential regulator of COMMD10. GO analysis demonstrated that COMMD10 and its interacting genes were mainly enriched in Cullin-RING ubiquitin ligase complexes, binding and transport of copper ions, the transport and steady-state maintenance of copper ions, transcription, translation and transport of proteins, and negatively regulate the activity of NF-kappaB transcription factors. KEGG pathway showed that COMMD10 and its interacting genes were mainly involved in renal cell carcinoma, HIF-1 signaling pathways, ubiquitination-mediated proteolysis, endocytosis and mineral absorption. COMMD10 may play a tumor suppressive role in renal clear cell carcinoma through the miR-590-3p-COMMD10-Cul2-RBX1-NF-κB/HIF/NRF2 pathway and regulate the chemotherapy resistance of various tumor cells to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30787448     DOI: 10.1038/s41417-019-0087-9

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  1 in total

1.  MiR-590-3p promotes proliferation and metastasis of colorectal cancer via Hippo pathway.

Authors:  Zhen-Qiang Sun; Ke Shi; Quan-Bo Zhou; Xiang-Yue Zeng; Jinbo Liu; Shuai-Xi Yang; Qi-San Wang; Zhen Li; Gui-Xian Wang; Jun-Min Song; Wei-Tang Yuan; Hai-Jiang Wang
Journal:  Oncotarget       Date:  2017-07-22
  1 in total
  8 in total

1.  Exploring prognostic value and regulation network of PPP1R1A in hepatocellular carcinoma.

Authors:  Xixi Wu; Yin Wang; Mi Yang; Yingqiao Wang; Xiaoqing Wang; Longshan Zhang; Liwei Liao; Nan Li; Mengyuan Mao; Jian Guan; Feng Ye
Journal:  Hum Cell       Date:  2022-08-26       Impact factor: 4.374

2.  Expression profile of SYNE3 and bioinformatic analysis of its prognostic value and functions in tumors.

Authors:  Liwei Liao; Longshan Zhang; Mi Yang; Xiaoqing Wang; Weiqiang Huang; Xixi Wu; Hua Pan; Lu Yuan; Wenqi Huang; Yuting Wu; Jian Guan
Journal:  J Transl Med       Date:  2020-09-18       Impact factor: 5.531

3.  Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer.

Authors:  Xiaotong Duan; Simiao Qiao; Dianhe Li; Shangbiao Li; Zhihao Zheng; Qin Wang; Xiaoxia Zhu
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

4.  Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis.

Authors:  Mi Yang; Weiqiang Huang; Yaling Sun; Huazhen Liang; Min Chen; Xixi Wu; Xiaoqing Wang; Longshan Zhang; Xiaoya Cheng; Yao Fan; Hua Pan; Longhua Chen; Jian Guan
Journal:  Br J Cancer       Date:  2019-09-16       Impact factor: 7.640

5.  Carbohydrate Sulfotransferase 4 Inhibits the Progression of Hepatitis B Virus-Related Hepatocellular Carcinoma and Is a Potential Prognostic Marker in Several Tumors.

Authors:  Longshan Zhang; Yao Fan; Xiaoqing Wang; Mi Yang; XiXi Wu; Weiqiang Huang; Jin Lan; Liwei Liao; Wenqi Huang; Lu Yuan; Hua Pan; Yuting Wu; Longhua Chen; Jian Guan
Journal:  Front Oncol       Date:  2020-10-15       Impact factor: 6.244

Review 6.  Commander Complex-A Multifaceted Operator in Intracellular Signaling and Cargo.

Authors:  Saara Laulumaa; Markku Varjosalo
Journal:  Cells       Date:  2021-12-07       Impact factor: 6.600

7.  COMMD10 inhibits tumor progression and induces apoptosis by blocking NF-κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma.

Authors:  Mi Yang; Xixi Wu; Lu Li; Shaoqun Li; Nan Li; Mengyuan Mao; Suming Pan; Richang Du; Xiaoqing Wang; Min Chen; Nanjie Xiao; Xiaohui Zhu; Guoyang He; Longshan Zhang; Weiqiang Huang; Hua Pan; Lan Deng; Longhua Chen; Li Liang; Jian Guan
Journal:  Clin Transl Med       Date:  2021-05

8.  SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.

Authors:  Lu Yuan; Xixi Wu; Longshan Zhang; Mi Yang; Xiaoqing Wang; Wenqi Huang; Hua Pan; Yuting Wu; Jihong Huang; Wenyu Liang; Jiaxin Li; Xiaodi Zhu; Shuang Wang; Jian Guan; Laiyu Liu
Journal:  Cancer Immunol Immunother       Date:  2021-06-28       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.